<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="231072">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00070317</url>
  </required_header>
  <id_info>
    <org_study_id>GOG-0206</org_study_id>
    <secondary_id>NCI-2012-02559</secondary_id>
    <secondary_id>CDR0000331918</secondary_id>
    <secondary_id>GOG-0206</secondary_id>
    <secondary_id>GOG-0206</secondary_id>
    <secondary_id>U10CA027469</secondary_id>
    <nct_id>NCT00070317</nct_id>
  </id_info>
  <brief_title>Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer</brief_title>
  <official_title>Lymphatic Mapping and Sentinel Node Identification in Patients With Stage1B1 Cervical Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gynecologic Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Gynecologic Oncology Group</source>
  <brief_summary>
    <textblock>
      This clinical trial is studying how well lymph node mapping and sentinel lymph node
      identification work in finding lymph node metastases in patients with stage IB1 cervical
      cancer. Diagnostic procedures, such as lymph node mapping and sentinel lymph node
      identification, performed before and during surgery, may improve the ability to detect lymph
      node metastases in patients who have cervical cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      I. Determine the sensitivity of the sentinel lymph node in the determination of lymph node
      metastases, using preoperative or intraoperative lymphatic mapping, in patients with stage
      IB1 cervical cancer.

      II. Determine the false-negative predictive value of the sentinel lymph node in the
      determination of lymph node metastases in these patients.

      OUTLINE: This is a multicenter study.

      Patients receive radiolabeled technetium Tc 99m sulfur colloid injected around the tumor 6
      hours prior to or after induction of anesthesia right before surgery. Patients then undergo
      radical hysterectomy and complete pelvic and low para-aortic lymphadenectomy.
      Intraoperatively, patients undergo lymphatic mapping and sentinel lymph node identification
      using isosulfan blue or methylene blue injected at 4 locations in the cervix and a hand-held
      gamma counter.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>June 2004</start_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity, defined as the proportion of patients who test as SN (+) among the patients who have LN metastases (LN+)</measure>
    <time_frame>At the time of surgery</time_frame>
    <description>The confidence interval of the sensitivity will be calculated by appropriate method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success rate of SN identification</measure>
    <time_frame>Up to 8 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Cervical Adenocarcinoma</condition>
  <condition>Cervical Adenosquamous Carcinoma</condition>
  <condition>Cervical Squamous Cell Carcinoma</condition>
  <condition>Stage I Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>Diagnostic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive radiolabeled technetium Tc 99m sulfur colloid injected around the tumor 6 hours prior to or after induction of anesthesia right before surgery. Patients then undergo radical hysterectomy and complete pelvic and low para-aortic lymphadenectomy. Intraoperatively, patients undergo lymphatic mapping and sentinel lymph node identification using isosulfan blue or methylene blue injected at 4 locations in the cervix and a hand-held gamma counter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isosulfan Blue</intervention_name>
    <description>Undergo lymphangiography using isosulfan blue or methylene blue</description>
    <arm_group_label>Diagnostic</arm_group_label>
    <other_name>Lymphazurin</other_name>
    <other_name>N-[4-[(4-(diethylamino)phenyl)(2,5-disulfophenyl)methylene]-2,5-cyclohexadien-1-ylidene]-N-ethyl-ethanaminium hydroxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lymph Node Mapping</intervention_name>
    <description>Undergo lymphatic mapping</description>
    <arm_group_label>Diagnostic</arm_group_label>
    <other_name>lymphatic mapping</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lymphangiography</intervention_name>
    <description>Undergo lymphangiography using isosulfan blue or methylene blue</description>
    <arm_group_label>Diagnostic</arm_group_label>
    <other_name>Lymphography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylene Blue</intervention_name>
    <description>Undergo lymphangiography using isosulfan blue or methylene blue</description>
    <arm_group_label>Diagnostic</arm_group_label>
    <other_name>Azul de Metileno</other_name>
    <other_name>Azul Metile</other_name>
    <other_name>Blu di Metilene</other_name>
    <other_name>CI Basic Blue 9</other_name>
    <other_name>CI-52015</other_name>
    <other_name>Collubleu</other_name>
    <other_name>Colour Index No. 52015</other_name>
    <other_name>Desmoidpillen</other_name>
    <other_name>Methylenum Caeruleum</other_name>
    <other_name>Methylthioninii Chloridum</other_name>
    <other_name>Methylthioninium Chloride</other_name>
    <other_name>Schultz No. 1038</other_name>
    <other_name>Tetramethylthionine Chloride Trihydrate</other_name>
    <other_name>Urolene Blue</other_name>
    <other_name>Vitableu</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radionuclide Imaging</intervention_name>
    <description>Undergo radionuclide imaging with technetium Tc 99m sulfur colloid</description>
    <arm_group_label>Diagnostic</arm_group_label>
    <other_name>nuclear medicine scan</other_name>
    <other_name>radioimaging</other_name>
    <other_name>Radionuclide Scanning</other_name>
    <other_name>Scan</other_name>
    <other_name>SCINTIGRAPHY</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel Lymph Node Biopsy</intervention_name>
    <description>Undergo complete pelvic and low para-aortic lymphadenectomy</description>
    <arm_group_label>Diagnostic</arm_group_label>
    <other_name>Sentinel Node Biopsy</other_name>
    <other_name>Sentinel node biopsy alone</other_name>
    <other_name>SLNB</other_name>
    <other_name>SNB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Technetium Tc-99m Sulfur Colloid</intervention_name>
    <description>Undergo radionuclide imaging with technetium Tc 99m sulfur colloid</description>
    <arm_group_label>Diagnostic</arm_group_label>
    <other_name>Tc 99m Sulfur Colloid</other_name>
    <other_name>Tc-99m SC</other_name>
    <other_name>Technetium Tc 99m Sulfur Colloid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Therapeutic Conventional Surgery</intervention_name>
    <description>Undergo radical hysterectomy</description>
    <arm_group_label>Diagnostic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of carcinoma of the cervix of 1 of the following cellular types:

               -  Squamous cell carcinoma

               -  Adenocarcinoma

               -  Adenosquamous cell carcinoma

          -  Stage IB1 disease (no greater than 4 cm)

          -  No unequivocal evidence of metastases

          -  Adequate surgical candidate

          -  No known allergy to triphenylmethane compounds

          -  No prior pelvic irradiation

          -  No prior retroperitoneal surgery

          -  More than 4 weeks since prior cold knife or loop electrosurgical excision procedure
             (LEEP) cone biopsy

          -  Prior cone biopsy allowed provided current disease is stage IB1
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Charles Levenback</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gynecologic Oncology Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
    <country>India</country>
    <country>Spain</country>
  </removed_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 3, 2015</lastchanged_date>
  <firstreceived_date>October 3, 2003</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Adenosquamous</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Technetium Tc 99m Sulfur Colloid</mesh_term>
    <mesh_term>Methylene Blue</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
